Brief an VALEANT

Brief an Valeant

Mit Wirkung vom 16.04.2015 hat VALEANT Pharmaceuticals International Inc. das Provenge / Sipuleucel-T wieder vom europäischen Markt zurückgezogen. Dies ist die Information, die wir erhalten haben von den 4 deutschen Zentren, die bis dahin eine Provenge-Therapie angeboten hatten. Und dies, nachdem am 19.03. der G-BA einen Beschluss zur begrenzten Einführung von Provenge gefasst hatte.

Wir haben vom Vorstand des BNfPK einen Brief an den CEO von VALEANT geschrieben, den wir hier wiedergeben, auch unter dieser Adresse herunterladbar.

 

 

VALEANT Pharmaceuticals International Inc.

J. Michael Pearson, CEO

2150 St. Elzéar Blvd. West

Laval, Quebec H7L 48A

Canada

 

Hamburg, 02.06.2015

 

Dear Mr. Chairman J. Michael Pearson,

 

we are shocked at the fact that Provenge (Sipuleucel-t) was taken away from the European market by Valeant. Many castration-refractory prostate cancer patients in Europe will die earlier because of this withdrawal.

It's really sad, because strengthening our own immunity system has been the prostate cancer patients' greatest wish for years. Provenge is greatly craved for by us, because it is the only cancer immune therapy which was licensed by FDA and EMA and which leads to a significant life extension.

What are Valeant's reason for withholding a licensed and effective immune therapy from the patients? We fear that your decision might be due to the shareholder value: the European market is supposed to be less profitable than the US market as regards the sale of Provenge. But you, as a pharmaceutical company, are also morally responsible to supply the patients, who are threatened by death, with the medicines which are effective against cancer.

 

With many regards

Rudolf Stratmann

Sepp Blaim

Malte Rathmann